GlassScriptPhysician profile
Liliana E Rios Rojas
NPI 1598027930
$5,812.28
in general payments reported to CMS, 2019-2025
18 companies · $1,800 in 2025
The $1,800 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $188 · 2021: $517 · 2022: $956 · 2023: $763 · 2024: $1,294 · 2025: $1,800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,815 · Education: $41.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,815.19 |
| Education | $41.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $2,465.95 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $727.91 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $612.89 | 2021-2023 | Krystexxa |
| Akebia Therapeutics INC | $500.18 | 2019-2024 | Auryxia, Vafseo |
| Travere Therapeutics, INC. | $478.60 | 2022-2025 | Filspari |
| Amgen INC. | $214.08 | 2024-2025 | Krystexxa, Tavneos |
| Fresenius USA Marketing, INC. | $146.26 | 2024-2025 | Velphoro, Velphoro |
| Sanofi-Aventis U.S. LLC | $143.09 | 2025 | |
| Neurocrine Biosciences, INC. | $123.76 | 2025 | |
| Lilly USA, LLC | $116.91 | 2025 | Mounjaro |
| Novo Nordisk INC | $107.82 | 2025 | Rivfloza |
| Dexcom, INC. | $44.37 | 2025 | Dexcom G6 Transmitter |
| Calliditas Therapeutics US INC. | $28.83 | 2024 | |
| Glaxosmithkline, LLC. | $23.47 | 2023 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $21.83 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Manufacturing, INC. | $20.57 | 2022 | |
| Insulet Corporation | $20.26 | 2024 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.50 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liliana Rios Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.